Want to see IN:AKUMS full AI Analyst Report?

Akums Drugs and Pharmaceuticals Limited (AKUMS) Price & Analysis

4 Followers

AKUMS Stock Chart & Stats

₹684.40

-₹11.70(-1.70%)

At close: Jul 27 4:00 PM EDT

₹684.40

-₹11.70(-1.70%)

Day’s Range― - ―

52-Week Range₹410.10 - ₹783.80

Previous CloseN/A

Volume178.53K

Average Volume (3M)11.50K

Market Cap

₹121.59B

Enterprise Value₹56.30K

Total Cash (Recent Filing)₹16.78B

Total Debt (Recent Filing)₹902.87M

Price to Earnings (P/E)40.6

Beta1.13

Next Earnings

Nov 09, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.39%

Share Statistics

EPS (TTM)12.42

Shares Outstanding157,393,980

10 Day Avg. Volume12,021

30 Day Avg. Volume11,497

Financial Highlights & Ratios

PEG Ratio-1.07

Price to Book (P/B)2.15

Price to Sales (P/S)1.64

P/FCF Ratio7.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)26.73

Revenue Forecast (FY)₹49.50B

Bulls Say, Bears Say

Bulls Say

Revenue GrowthThe multi-year revenue increase indicates expanding scale for Akums’ contract manufacturing platform. Its broad finished-dosage portfolio and repeat client relationships can support continued volume growth across domestic and export markets.

Stronger Balance SheetA sharply lower debt burden and materially larger equity base improve financial resilience and reduce funding pressure. This gives Akums greater flexibility to maintain operations and invest in manufacturing capacity or development capabilities.

Improved Cash GenerationStrong FY26 operating and free cash flow provides internally generated funding for capital needs and debt avoidance. Free cash flow covered about 81% of net income, indicating substantially improved cash conversion in the latest period.

Bears Say

Margin CompressionThe steep FY26 margin decline shows that revenue growth is not translating consistently into profit. Persistent cost pressure, adverse product mix, or one-off effects could limit earnings durability and reduce operating leverage.

Earnings VolatilityNegative EPS growth and the easing of returns in FY26 point to uneven earnings momentum after the turnaround. Such volatility makes it harder to assess sustainable profitability and increases dependence on execution and product mix.

Uneven Cash ConversionAlthough recent cash generation is strong, the earlier pattern of weak operating cash flow relative to earnings indicates working-capital or business-cycle sensitivity. A return of this volatility could constrain reinvestment and reduce cash-flow reliability.

Akums Drugs and Pharmaceuticals Limited News

Akums to Acquire Oriflame India’s Manufacturing Assets for ₹56 Crore

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) just unveiled an announcement. Akums Drugs and Pharmaceuticals Limited has...

1M ago

AKUMS

ICRA Reaffirms Akums Ratings and Assigns Top Grade to New Commercial Paper

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) just unveiled an update. Akums Drugs and Pharmaceuticals Limited has...

5M ago

AKUMS

Akums Closes Trading Window Ahead of Q3 FY2025 Unaudited Results

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an announcement. Akums Drugs and Pharmaceuticals Limited has...

8M ago

AKUMS

Akums Secures Patent for Innovative GERD Treatment

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has shared an announcement. Akums Drugs and Pharmaceuticals Limited has...

10M ago

AKUMS

Akums Drugs Expands with New Subsidiary in Malta

The latest update is out from Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ). Akums Drugs and Pharmaceuticals...

10M ago

AKUMS

Akums Expands with New Joint Venture in Zambia

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an update. Akums Drugs and Pharmaceuticals Limited has...

11M ago

AKUMS

AKUMS FAQ

What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?

Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹783.80 in the past 12 months.

What is Akums Drugs and Pharmaceuticals Limited’s market cap?

Akums Drugs and Pharmaceuticals Limited’s market cap is ₹121.59B.

When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?

Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Nov 09, 2026 which is in 71 days.

How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?

Akums Drugs and Pharmaceuticals Limited released its earnings results on Aug 08, 2026. The company reported ₹6.4 earnings per share for the quarter, beating the consensus estimate of ₹6.1 by ₹0.3.

Is Akums Drugs and Pharmaceuticals Limited overvalued?

According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Akums Drugs and Pharmaceuticals Limited pay dividends?

Akums Drugs and Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.39%. See more information on Akums Drugs and Pharmaceuticals Limited dividends here

What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?

Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?

Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.

What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?

Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹6.4 in its last earnings report, beating expectations of ₹6.1. Following the earnings report the stock price went down -2.69%.

Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:AKUMS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Akums Drugs and Pharmaceuticals Limited

Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (APIs). Its diverse product range encompasses conventional drugs, traditional Ayurvedic and herbal remedies, personal care items including toiletries, nutraceuticals, food and dietary supplements, dermatological and cosmetic products, and healthcare and hospital supplies, along with over-the-counter (OTC) solutions. The company also deals in excipients and various chemical compounds. Akums develops and markets its own branded formulations across a variety of dosage forms, such as tablets, capsules, injectables, ophthalmic preparations, and soft gelatin capsules. These products address a broad spectrum of therapeutic areas, including gynaecology, cardiology, orthopaedics, pediatrics, dermatology, anti-infectives, pain management, and gastroenterology. Furthermore, Akums Drugs & Pharmaceuticals provides services as a pharmaceutical contract development and manufacturing organization (CDMO).